StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) income statement

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.41+0.05 (+13.12%)

Close on Nov 18, 2026Market cap $99.30MP/E –Yield –

Outlook Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin
-161.0%
Operating margin
-3935.9%
Net margin
-4324.1%
Return on equity, FY2025
118.6%

Financial strength

Current ratio
0.81
Debt to equity
–
Debt to assets
–
Cash to current liabilities
39.2%

Valuation

P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–

See a number that looks wrong?